Repurposing News Articles
Repurposing News Articles
Embedded Files
NCATS News (add the Repurposing success stories)
NIH News
Other Government News
Other News
CBS NEWS 7-MAR-2021
Highlight: Dr. Collins describes NIH’s efforts through the ACTIV public-private partnership to identify FDA-approved drugs to repurpose for COVID-19 treatment.
https://c-path.org/c-path-launches-cure-drug-repurposing-collaboratory-to-accelerate-identification-of-new-uses-of-existing-drugs-to-treat-infectious-diseases-including-covid-19/
FDA 19-May-2021
Excerpt: FDA’s Clinical Methodologies Group (ClinMeth) within CDER’s Office of Medical Policy received a $9.2 million grant through the HHS Office of the Assistant Secretary for Planning and Evaluation’s (ASPE) Patient Centered Outcomes Research Trust Fund.
The ASPE grant will fund expansion of the CURE ID platform to allow automated data collection from electronic health records (EHR) worldwide and clinical disease registries for COVID-19 and other difficult-to-treat infectious diseases.
MEDPAGE Today 22-April-2021
Veronica Hackethal
Highlight: From high-throughput screening to poring through the literature, many paths to repurposing.
EurekAlert! NEWS RELEASE 22-DEC-2020
Highlight: In what has the potential to significantly change how Corona patients are being treated and the severity of the disease, research spearheaded at Jerusalem's Hebrew University gathered early clinical evidence demonstrating the efficacy of an existing drug in treating COVID-19. The study was presented at the recent SPARK Conference on Generic Drug Repurposing for COVID-19 by Professor Yaakov Nahmias, Director of the Center for Bioengineering at Hebrew University. Nahmias applied a well-established existing drug to address the buildup of fats in human lung cells caused by the SARS-CoV-2 virus. Initial lab-based results and new data from 1,500 Israel-based Corona patients have been extremely promising and clinical studies are scheduled to begin this week at Barzilai Hospital in Ashkelon, Israel, joining other clinical centers across the United States, South America and Europe.
NC State University News Blog March 30, 2020
Tracey Peake
Highlight: Researchers from North Carolina State University have found that a commonly used drug made from secondary bile acids can affect the life cycle of Clostridioides difficile (C. diff) in vitro and reduce the inflammatory response to C. diff in mice. The findings aid understanding of how this drug may be used in future treatment of C. diff infections in humans.
EurekAlert! NEWS RELEASE 19-MAR-2020
Highlight: Statins are widely used to lower cholesterol and prevent heart disease and related deaths, but can they also help guard against heart damage caused by certain breast cancer therapies? New research being presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC) suggests the answer may be yes.
EurekAlert! NEWS RELEASE 28-FEB-2020
Highlight: Researchers from the University of Tsukuba have shown by in vivo experimentation on a mouse model that angioimmunoblastic T-cell lymphoma (AITL) is highly dependent on T-cell receptor (TCR) signaling. Further trials also suggest that dasatinib, a multi-kinase inhibitor that targets the TCR pathway, may improve treatment outcomes in both the mouse model and in a clinical trial of five patients who relapsed or were refractory to conventional therapy and therefore showed promise as a candidate drug for AITL treatment.
EurekAlert! NEWS RELEASE 27-FEB-2020
Highlight: A targeted therapy drug used for breast and kidney cancers may also extend progression-free survival for patients with advanced head and neck cancer who are at high risk for recurrence after standard treatment. Patients enrolled in a randomized phase II trial who received the mTOR inhibitor everolimus were more likely to be cancer-free a year after therapy than those who took a placebo drug, and the benefit persisted for those with mutations in their TP53 gene. The findings may present a new treatment option for a group of patients whose survival rates have not improved in more than 30 years. The study will be presented at the 2020 Multidisciplinary Head and Neck Cancers Symposium, taking place February 27-29 in Scottsdale, Arizona.
The New York Times Opinion Section February 25, 2020
Sophie Cousins
Highlight: While doctors are allowed to use drugs approved for one disease to treat another condition, many don’t because approval to do so doesn’t appear on the label. But that may be changing.
Fierce Biotech Research Blog
Arlene Weintraub | Feb 24, 2020
Highlight: Lung cancer patients with EGFR mutations often respond to targeted treatments but then become resistant in a few short months. Now, researchers led by a team at the University of Toronto believe they’ve found a way to correct this drug resistance with two recently approved medicines for leukemia.
Using a cell-based technology developed at the university’s Donnelly Centre for Cellular and Biomolecular Research, the researchers hit upon Astellas’ Xospata (gilteritinib) and Novartis’ Rydapt (midostaurin) as potential treatments for non-small cell lung cancer (NSCLC) with triple-mutant EGFR. They are now planning human trials, starting with Astellas’ product, they reported in the journal Nature Chemical Biology.
Anticancer Fund 2020
Highlight: Drug repurposing, also known as drug repositioning, is a drug development strategy predicated on the reuse of existing licensed drugs for new medical indications. How can we ensure accessible, sustainable and affordable cancer care in Europe? Repurposing existing medicines offers a cost-efficient way to increase cancer patients’ treatment options. Find out the untapped potential of drug repurposing and how policy makers can help, in this video!
Science Translational Medicine: In the Pipeline Blog 2014
Derek Lowe
Highlight: A reader has sent along the question: “Have any repurposed drugs actually been approved for their new indication?” And initially, I thought, confidently but rather blankly, “Well, certainly, there’s. . . and. . .hmm”, but then the biggest example hit me: thalidomide. It was, infamously, a sedative and remedy for morning sickness in its original tragic incarnation, but came back into use first for leprosy and then for multiple myeloma. The discovery of its efficacy in leprosy, specifically erythema nodosum laprosum, was a complete and total accident, it should be noted – the story is told in the book Dark Remedy. A physician gave a suffering leprosy patient the only sedative in the hospital’s pharmacy that hadn’t been tried, and it had a dramatic and unexpected effect on their condition.
C&EN (Chemical & Engineering News) 2012
Highlight: This fall, at least three conferences will bring together researchers to discuss how finding new uses for known drug compounds can be a strategy for both clinical development and business growth. A few years ago, no such conferences existed. The attendee lists show that interest is widespread among large pharmaceutical companies, small biotech firms, government agencies, academic groups, and nonprofit organizations alike.
Page updated
Report abuse